A single centre, longitudinal, observational cohort study investigating the effects of ivacaftor/lumacaftor on respiratory microbial composition and microbial metabolic activity by repeatedly sampling the lower respiratory tract
Latest Information Update: 23 Dec 2020
At a glance
- Drugs Ivacaftor/lumacaftor (Primary)
- Indications Cystic fibrosis; Cystic fibrosis-associated respiratory tract infections
- Focus Therapeutic Use
- 23 Dec 2020 New trial record